REG - Oxford Cannabinoid - Formation of Scientific Advisory Board

Oxford Cannabinoid Technologies HoldingsAnnouncement

25/04/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220425:nRSY1324Ja&default-theme=true

RNS Number : 1324J  Oxford Cannabinoid Tech.Holdings  25 April 2022

25 April 2022

Oxford Cannabinoid Technologies Holdings plc

("OCTP", or the "Company")

Formation of Scientific Advisory Board to Support Clinical Strategy

 

Oxford Cannabinoid Technologies Holdings plc (LSE: OCTP, OTCQB: OCTHF), the
pharmaceutical company developing prescription cannabinoid medicines targeting
the US$ multi-billion pain market is pleased to announce the formation of its
Scientific Advisory Board ("SAB").

 

With the Company's current focus on the treatment of neuropathic pain
conditions, the composition of the SAB will initially comprise Professor
Robert Dworkin, Professor Anthony Dickenson, and Doctor Giorgio Lambru,
together a team of innovators and clinicians with an emphasis on linking
pre-clinical research, clinical trials and the care of patients. The SAB will
work closely with OCTP's Chief Scientific Officer, Doctor Valentino
Parravicini, to provide scientific guidance on the Company's strategy and
overall approach to clinical trials. Its initial focus will be to advise on
the design of the Company's upcoming phase 1 clinical trials for OCT130401 and
OCT461201, anticipated in Q4 2022 and Q1 2023 respectively, to help OCTP best
address the needs of patients. The SAB will also help to shape the Company's
approach as it looks beyond phase 1, to phase 2 clinical trials, in patients
affected by debilitating pain conditions.

Professor Robert Dworkin, who has been a consultant to the Company since
November 2021, is a Professor in the departments of Anesthesiology and
Perioperative Medicine, Neurology, and Psychiatry at the University of
Rochester Medical Center School of Medicine and Dentistry, New York State. He
is also a Director of ACTTION (Analgesic, Anesthetic, and Addiction Clinical
Trial Translations, Innovations, Opportunities, and Networks) a public-private
partnership with the United States Food and Drug Administration. Professor
Dworkin's major research interests are the methodologic aspects of analgesic
clinical trials and the treatment and prevention of chronic neuropathic and
musculoskeletal pain. Through ongoing studies he is evaluating the research
designs and methods, clinical outcome assessments, and statistical analyses
used in clinical trials of treatments for acute and chronic pain.

 

Doctor Giorgio Lambru, who has been a consultant to the Company since February
2022, is a Consultant Neurologist at Guy's & St Thomas' NHS Foundation
Trust, London, and Honorary Senior Lecturer at King's College London. Dr
Lambru is an expert in headache and facial pain conditions, including
neuropathic pain and general neurology conditions. He has authored a number of
scientific publications on these conditions and has a clinic dedicated to
complex headache and facial pain disorders.

Professor Anthony Dickenson, who has been a consultant to the Company since
May 2021, is Emeritus Professor of Neuropharmacology at University College,
London. Professor Dickenson's research is focused on understanding the
mechanisms of pain including how pain can be controlled in both normal and
patho-physiological conditions and how to translate basic science to patients.
He is an Honorary Member of the British Pain Society, a member of the council
of the International Association for the Study of Pain, was a founding member
of the London Pain Consortium (Welcome Trust), and is involved in many
advisory boards.

The formation of the SAB underpins the next stage of the Company's development
and highlights its commitment to grow a best-in-class network of partners -
scientific, academic and commercial.

 

OCTP Chief Scientific Officer, Doctor Valentino Parravicini said:

 

"Our research ethos is to develop breakthrough therapies for debilitating pain
conditions with significant as yet unmet medical needs. We are honoured and
delighted to formalise our relationships with Professors Robert Dworkin and
Anthony Dickenson and Doctor Giorgio Lambru as our SAB, whose combined
experience and advice in developing our drug candidates will, we are sure, be
invaluable."

The Directors of the Company accept responsibility for the content of this
announcement.

 

Enquiries:

 Oxford Cannabinoid Technologies Holdings plc  +44 (0)20 3034 2820

 Dr John Lucas (CEO)                           john@oxcantech.com

 Clarissa Sowemimo-Coker (COO)                 clarissa@oxcantech.com

 Cairn Financial Advisers

 Emily Staples                                 +44 (0)20 7213 0897

 Jo Turner                                     +44 (0) 20 7213 0885

 Walbrook PR Limited                           +44 (0)20 7933 8780

 Paul Vann                                     +44 (0)7768 807631

 Nick Rome                                     oxcantech@walbrookpr.com

 Harbor Access LLC (US/OTCB enquiries)

 Jonathan Paterson                             +1 (203) 862 0492

 Richard Leighton                              Richard.Leighton@harboraccessllc.com

 

About Oxford Cannabinoid Technologies Holdings Plc:

Oxford Cannabinoid Technologies Holdings plc ("OCTP") is the holding company
of Oxford Cannabinoid Technologies Ltd ("OCT"), a pharmaceutical company
developing prescription cannabinoid medicines for approval by key medicines
regulatory agencies worldwide and targeting the U$ multi-billion pain
market (together the "Group"). Cannabinoids are compounds found in the
cannabis plant that have been shown to have a range of therapeutic effects on
the body, including pain relief. The Group has a clearly defined path to
commercialisation, revenues and growth. The Group is developing drug
candidates through clinical trials to gain regulatory approval (FDA/MHRA/EMA)
that will enable medical professionals to prescribe them with confidence.

The Group's portfolio aims to balance risk, value and time to market, whilst
ensuring market exclusivity around all its key activities. The Group's lead
compound, OCT461201, is a highly potent and selective CB2 agonist and is being
developed by OCT in a solid oral dosage form. OCT is conducting pre-clinical
testing and development with clinical trials scheduled for Q1 2023. The
Group's product pipeline also uses a balanced drug product strategy that
employs both natural and synthetic compounds for the treatment of rare
diseases and includes chemically modified phytocannabinoids with improved
drug-like characteristics and a proprietary library of cannabinoids.

OCTP operates a partnership model with external academic and commercial
partners.

 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward
looking statements. Forward looking statements are identified by their use of
terms and phrases such as ''believe'', ''could'', "should" ''envisage'',
''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect",
''will'' or the negative of those, variations or comparable expressions,
including references to assumptions. These forward-looking statements are not
based on historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of operations,
performance, future capital and other expenditures (including the amount,
nature and sources of funding thereof), competitive advantages, business
prospects and opportunities. Such forward looking statements reflect the
Directors' current beliefs and assumptions and are based on information
currently available to the Directors.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDBGDSCUDDGDS